Autobrains Unveils Skills Product Line, Redefining Autonomous Driving With Scalable and Modular AI Solutions
New Liquid AI-Powered Skills Solution Offers a Modular, Optimized for Edge Cases, and Affordable Alternative to Existing Autonomous Driving Approaches
MUNICH, GERMANY and TEL AVIV, ISRAEL / ACCESSWIRE / October 22, 2024 / Autobrains, a leading innovator in automotive artificial intelligence (AI) and advanced driver assistance systems (ADAS), is proud to announce the launch of its groundbreaking product line, Skills, powered by its proprietary Liquid AI technology.
Each Skill, End-to-End AI, is optimized for a specific driving scenario.
The Skills product line represents a significant leap in autonomous driving technology, offering modular, scalable solutions that effectively address edge cases while reducing computational requirements compared to existing approaches.
As the automotive industry accelerates toward full autonomy, Autobrains' new approach tackles the key limitations of traditional AI models by introducing a flexible and adaptive solution. While current end-to-end systems rely on a single, large neural network, or complex, resource-heavy compound systems, Autobrains' Skills solution delivers superior adaptability and efficiency.
"Our Skills product line represents a paradigm shift in autonomous driving," said Igal Raichelgauz, Founder and CEO of Autobrains. "With Skills, we offer a flexible, scalable AI solution that can be deployed incrementally, starting with ADAS and extending toward full autonomy. Unlike other approaches, our system's adaptability ensures that as new edge cases emerge, the required resources increase only logarithmically, providing a significant improvement over demands seen with other approaches."
Existing autonomous driving solutions face substantial challenges in handling edge cases, which demand new, more adaptive AI technologies. Compound architectures, like those employed by Mobileye, divide tasks into separate modules, resulting in an information bottleneck. Monolithic end-to-end systems like Tesla's Full Self-Driving (FSD) suite face issues with explainability, transparency, and efficiency in adapting to new scenarios.
Autobrains' Skills architecture addresses these issues by decomposing autonomous driving into a collection of smaller, context-specific AI models - referred to as "Skills"-each trained and deployed independently. These Skills are activated dynamically based on the driving situation, optimizing performance and significantly reducing computational power demands.
Key advantages of the Autobrains' Skills product line include:
Optimized for Edge Cases: Each Skill is optimized to handle specific driving scenarios, leading to superior performance in edge cases.
Scalability: The Skills architecture can expand from tens of skills for ADAS applications to hundreds of thousands for full autonomy.
Adaptability: Skills are activated only when relevant, minimizing power consumption.
Logarithmic Resource Growth: Unlike models that require exponentially more resources as they scale, the Skills architecture allows for more efficient, logarithmic resource expansion.
Enhanced Safety: By focusing on specific edge cases, Skills provide precise, targeted responses, enhancing overall system safety.
Autobrains is actively collaborating with major OEMs worldwide, testing and implementing the Skills product line to transform the future of autonomy. This cutting-edge AI architecture is poised to lower costs, improve safety, and drive the next wave of smarter, more efficient autonomous driving systems.
For more information about Autobrains and its Skills technology, please visit www.autobrains.ai.
Contact Information
Sophia Eichler
Director of Marketing
media@autobrains.ai
+49 15167066494
SOURCE: Autobrains
View the original press release on newswire.com.
Autobrains
Subscribe to releases from Accesswire
Subscribe to all the latest releases from Accesswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Accesswire
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections10.12.2024 07:30:00 CET | Press Release
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites. RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular thera
Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press Release
During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h
Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press Release
WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press Release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 20245.12.2024 09:10:00 CET | Press Release
Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure Register for the event here HOUSTON, TX / ACCESSWIRE / December 5, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it will host a Virtual Analyst & Investor Day on Wednesday, December 11th from 11:30 AM - 1:00 PM ET. For the event, John Climaco, Chief Executive Officer, Sandra Silberman, MD, PhD, Chief Medical Officer and Zena Muzyczenko, Vice President of Clinical Operations at CNS Pharmaceuticals will be joined by Key Opinion Leaders: Michael Weller, Prof. Dr. med. Director of Department, Department of Neurology, Universitatsspital, Zur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom